In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In US Drug Pricing Debate, ICER’s Voice Gets Louder

The Biggest Mistake For Pharma Is Failing To Engage With ICER

Executive Summary

ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.

You may also be interested in...



AbbVie And Biogen Make ICER's Unsupported Price Increase List Three Years Running

ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.

Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?

The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Topics

Latest News
See All
UsernamePublicRestriction

Register

IV124375

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel